Am­gen part­ners with Genen­ta, San Raf­faele on an an­ti-tu­mor drug

The gene ther­a­py ex­perts at Italy’s San Raf­faele Hos­pi­tal and Sci­en­tif­ic In­sti­tute (Os­pedale San Raf­faele, OSR) and its spin­out Genen­ta Sci­ences are col­lab­o­rat­ing with Am­gen on new tu­mor pro­grams. The part­ners will “de­vel­op an in­no­v­a­tive ther­a­py based on gene trans­fer in­to au­tol­o­gous hematopoi­et­ic Stem Cells to ex­press spe­cif­ic an­ti-tu­mor pro­teins in their prog­e­ny.” “Am­gen is the per­fect part­ner for us due to their lead­er­ship in on­col­o­gy and com­mit­ment in ex­plor­ing in­no­v­a­tive tech­nolo­gies,” stat­ed Pier­lui­gi Parac­chi, Genen­ta’s Chair­man and Chief Ex­ec­u­tive Of­fi­cer. “We are proud to an­nounce this col­lab­o­ra­tion to ex­ploit our HSCs gene ther­a­py plat­form.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.